HIV-1 Tropism Testing and Clinical Management of CCR5 Antagonists: Quebec Review and Recommendations | Zendy

Cécile Tremblay | Zendy; Isabelle Hardy | Zendy; Richard Lalonde | Zendy; Benoît Trottier | Zendy; Irina Tsarevsky | Zendy; LouisPhilippe Vézina | Zendy; Michel Roger | Zendy; Mark A. Wainberg | Zendy; Jean-Guy Baril | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HIV-1 Tropism Testing and Clinical Management of CCR5 Antagonists: Quebec Review and Recommendations

Author(s) -

Cécile Tremblay,

Isabelle Hardy,

Richard Lalonde,

Benoît Trottier,

Irina Tsarevsky,

LouisPhilippe Vézina,

Michel Roger,

Mark A. Wainberg,

Jean-Guy Baril

Publication year - 2013

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.634

H-Index - 38

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/2013/982759

Subject(s) - maraviroc , ccr5 receptor antagonist , tropism , tissue tropism , preclinical testing , genotyping , clinical trial , medicine , human immunodeficiency virus (hiv) , virology , biology , genotype , chemokine receptor , medical physics , virus , receptor , genetics , chemokine , gene

HIV-1 tropism assays play a crucial role in determining the response to CCR5 receptor antagonists. Initially, phenotypic tests were used, but limited access to these tests prompted the development of alternative strategies. Recently, genotyping tropism has been validated using a Canadian technology in clinical trials investigating the use of maraviroc in both experienced and treatment-naive patients. The present guidelines review the evidence supporting the use of genotypic assays and provide recommendations regarding tropism testing in daily clinical management.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research